Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02037425 · ClinicalTrials.gov registry record · Phase 4
Duration of Benefit for OnabotulinumtoxinA in Treatment of Chronic Migraine
A Phase 4 study, sponsored by Cady, Roger, M.D..
- Completed
- Registry status
- Phase 4
- Development phase
- 44
- Enrollment target
NCT02037425: Completed Phase 4 study, sponsored by Cady, Roger, M.D..
NCT02037425 is a Phase 4 study that has completed, run by Cady, Roger, M.D.. The registered enrollment target is 44 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02037425, a Phase 4 study, has completed, sponsored by Cady, Roger, M.D..
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 44 participants
- Enrollment target
Study Summary
To obtain a patient specific understanding of response to treatment with onabotulinumtoxinA by collecting and correlating pre and post treatment subject specific history, clinical outcomes, and histological changes.
Primary Outcome
Changes in the Subject's Global Impression of Change (SGIC) measured at weeks 12, 24, and 36 for Groups A, B, and C. Subject global impression of change was measured on a 7 point scale with 0 being Very Much Worse and 7 Very Much Improved.
Interventions
- DRUG onabotulinumtoxinA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2014-04 |
| Est. Completion | 2015-09 |
| Phase | Phase 4 |
What the finished NCT02037425 record still lists
NCT02037425 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 44 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 1 intervention - of which onabotulinumtoxinA is the first listed.
NCT02037425 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02037425 about?
NCT02037425 is a clinical study titled "Duration of Benefit for OnabotulinumtoxinA in Treatment of Chronic Migraine". To obtain a patient specific understanding of response to treatment with onabotulinumtoxinA by collecting and correlating pre and post treatment subject specific history, clinical outcomes, and histological changes.
What is the current status of trial NCT02037425?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 44 participants. The study started on 2014-04. Estimated completion is 2015-09.
What interventions are being tested in trial NCT02037425?
The interventions under investigation include: onabotulinumtoxinA (DRUG).
Who is sponsoring clinical trial NCT02037425?
This trial is sponsored by Cady, Roger, M.D., which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02037425's enrollment target sits among peer trials
44 1363rd of 2000 higher than 630 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02323945 · 44 participants · NA
Effects of Breathing Mild Bouts of Low Oxygen on Limb Mobility After Spinal Injury
- NCT03093909 · 44 participants · Phase 1
Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
- NCT03104491 · 44 participants · Phase 1
Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
- NCT03781765 · 44 participants · Phase 4
Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia